Fisher Asset Management LLC Cuts Position in Haemonetics Corporation $HAE

Fisher Asset Management LLC lessened its position in Haemonetics Corporation (NYSE:HAE) by 6.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 689,142 shares of the medical instruments supplier’s stock after selling 45,401 shares during the quarter. Fisher Asset Management LLC owned 1.43% of Haemonetics worth $51,417,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in HAE. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Haemonetics by 7.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,396 shares of the medical instruments supplier’s stock valued at $851,000 after purchasing an additional 936 shares during the last quarter. Cary Street Partners Financial LLC purchased a new stake in Haemonetics in the first quarter worth approximately $1,082,000. Charles Schwab Investment Management Inc. grew its position in Haemonetics by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock valued at $35,336,000 after acquiring an additional 4,834 shares during the last quarter. Citigroup Inc. grew its position in Haemonetics by 87.3% during the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after acquiring an additional 291,574 shares during the last quarter. Finally, Zions Bancorporation National Association UT purchased a new position in shares of Haemonetics during the first quarter worth approximately $2,744,000. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on HAE. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Haemonetics in a research note on Monday. Barrington Research boosted their target price on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Mizuho dropped their target price on Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Friday, August 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.70.

Haemonetics Stock Down 0.3%

Shares of NYSE:HAE opened at $80.74 on Wednesday. The stock’s 50-day moving average is $59.77 and its 200 day moving average is $63.47. The company has a market cap of $3.78 billion, a PE ratio of 24.69, a P/E/G ratio of 0.91 and a beta of 0.29. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $88.03.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period last year, the company earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.